Equity partners have invested a total of $10 million and we are currently seeking an additional $2 million to close our Series A funding round.
Dreamtech has been our strategic investor and partner since 2018. Dreamtech is supporting NanoScent's electronic hardware components. In a statement from Dreamtech's CEO, Hyoung Min Kim believes “both companies are committed to the successful commercialization of ‘scent reader’ solutions worldwide... both companies will further strengthen the strategic partnership become a leading company in the healthcare market.”
In the news:
Since 2019, Sumitomo Chemical is one of our key strategic investors. Sumitomo Chemical took an interest in us because they see that a rapid diagnostic sensor has great long-term potential for other applications, in addition to COVID-19. Sumitomo Chemicals is backing us up so that we can reach our goals for scaling up and manufacturing chemical electronic components.
In the news:
Grants & Projects
Through grants and projects with Fortune 500 companies, we have raised about $9 million in non-dilutive funding.
The European Innovation Council supports NanoScent's project for developing a COVID-19 sensor.
The Israel Innovation Authority has been supportive through their COVID-19 research grant.